Pass S.3306/H.R.2985 – Modernizing Government Technology Reform Act
We urge swift passage of S.3306/H.R.2985, the Modernizing Government Technology Reform Act, a bipartisan, commonsense measure to reauthorize the Technology Modernization Fund (TMF) before it expires in September 2026.
TMF ensures federal agencies can cost-effectively upgrade critical national tech infrastructure, rather than wasting taxpayer dollars on outdated systems.
The federal government spends on average $100 billion on IT every year, yet agencies are trapped spending 80 cents of every taxpayer dollar on maintaining systems that predate the smartphone, the cloud, and in some cases, the internet itself. Reauthorizing TMF helps get the federal government out of this costly cycle, and has already shown measurable results in improving cybersecurity and operational efficiency.
We applaud the bipartisan leadership of Senators Jerry Moran (R-KS) and Gary Peters (D-MI) and Representatives Nancy Mace (R-SC), and Shontel Brown (D-OH) in working together to pass The Modernizing Government Technology Reform Act.
The Trump administration has said the Executive Branch needs TMF to continue, and Congress should reauthorize this cost-saving measure to modernize government technology.
Signed,
The Federation of American Scientists
Foundation for American Innovation Action
Partnership for Public Service
Niskanen Center State Capacity Initiative
Inclusive Abundance Action
Recoding America Action
This is a bipartisan, commonsense measure to reauthorize the Technology Modernization Fund (TMF) before it expires in September 2026.
Many states are introducing AI policies and task forces, but lack the “AI-native” personnel to build and maintain initiatives. To address this in the short term, states should establish AI Resilience Cohorts to embed early-career technologists in key offices to support state AI initiatives. Right now, Virginia and New Jersey have the opportunity to take […]
We sat down with biomedical research pioneer Lee Hood to talk moonshots, metascience in medicine, and the Human Phenome Initiative.
DNA synthesis and export controls remain the primary regulatory safeguards against de novo production of harmful biological agents, yet governance frameworks lack the situational awareness and enforcement capacity to keep pace with rapidly falling technical barriers.